ICCPP ODM+ Won Two Muse Design Gold Awards, Keeping Leading the Creative Design Trend
15.9.2023 15:00:00 EEST | Business Wire | Press release
Recently, the winners of MUSE Design Awards 2023, known as the Oscar Awards of the design, were announced, and ICCPP ODM+'s Cyclo eco-friendly e-cigarette and SPEEX X1, one of SPEEX dual-coils and screen display series display products, stood out and won Gold Awards of Muse Design from nearly 40,000 works worldwide, thanks to their advanced globalization vision, innovative user-centered design, and sustainable concepts of caring for both human beings and nature.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904756304/en/
ICCPP ODM+ Won MUSE DESIGN GOLD AWARDS (Photo: Business Wire)
MUSE Design Awards was founded in 2015 by International Awards Associates (IAA), a long-established U.S.-based international design awards association, and is one of the most influential international awards in the field of global creative design. The awards have always been known for their rigorous judging system and high quality standards, aiming to cultivate, promote and recognize excellence in the global design field, and promote the development of the global design industry to a higher level.
ICCPP ODM+ won the two design gold awards in one go in its first competition, which was not only a confirmation of its global leadership in future-oriented innovative product design, concepts and inspirations, but also a recognition of the strength of ICCPP Group's user-centered approach to deepening innovation and empowering the development of the e-atomization industry, and even set a new benchmark for global brands in e-cigarette product design.
It is understood that one of the Gold Award winners, SPEEX X1 is an independent innovative flagship product of the SPEEX heating technology series with high-capacity, dual coil and screen display from ICCPP ODM+, listed in August. It is a unique combination of dual-coil design with dual output working models and SPEEX rocket-like heating technology, and plus the small, rounded, extremely compact and aesthetic design, superimposed on the 0.73-inch oversized e-liquid and power remain screen display, SPEEX X1 achieves a perfect balance among the flavor, vapor, aesthetics and user thinking.
Cyclo, the other winner of Muse Design Gold Awards, is a new 2ml product launched by ICCPP ODM+ at VAPER EXPO UK2023 in May. Considering global trend of low carbon and environmentally friendly concept, coupled with the deep concerns of global users about increasingly serious environmental problems caused by the prevalence of disposable e-cigarettes, as well as the enforce reality of Europe's new Battery Law and some environmental protection acts, ICCPP ODM+ innovatively developed Cyclo, the world's first double environmentally-friendly concept disposable e-cigarettes solution. Through its innovative application of PLA degradable materials, coupled with lead-free and solder-free inner structures, and modularized and fully automated design, as well as the aesthetics of simple, rounded and hand-held shape, and the creative integration of the concepts of user detachable and biodegradable, Cyclo is ahead of the industry to achieve the balance of portability, artistry and recyclability for the users in advance.
While these two award-winning products are just a small microcosm of ICCPP ODM+'s human-centered, and user-first design philosophy. At ICCPP, we believe that design is not just about aesthetics, but should also keep upgrading user experience, meeting user needs and creating a more meaningful connection between people, society and nature. In the future, ICCPP ODM+ will continue to be committed to continuous innovation, to lead the design trend, to create more and more exciting and premium e-cigarette product solutions, and to bring a healthier and happier e-atomized life to vaping enthusiasts around the world.
For more information, please refer to: https://www.iccpp.com/
WARNING: This product contains nicotine which is a highly addictive substance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904756304/en/
Contact information
Media:
Carol, carol@iccpp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release
Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 09:00:00 EEST | Press release
Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to digital to manage their businesses. In late 2025, Tide received a strategic investment from TPG, a leading global alternative asset manager, valuing the company at $1.5 billion. Oliver Prill, CEO of Tide, said: “We are delighted to be crossing the 2 million member milestone. This number is a testament to the trust that our members place in us in all our markets. Behind every
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 01:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 20:00:00 EEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom